Pharma Archives - Page 2 of 4 - McAlinden Research Partners

★ Daily Intelligence Briefings (DIBs)⦁ Theme Tracker Biotechnology & Healthcare Finance Ⓛ Pharmaceuticals Markets

Pfizer’s M&A Strategy Sketches Roadmap for Pharma to Rebuild Pipelines, Overcome Patent Cliffs

Pfizer's acquisition of Seagen, which is the largest biopharma deal since 2019, comes as products received in previous deals begin…

McAlinden Research PartnersMarch 14, 2023

★ Daily Intelligence Briefings (DIBs)⦁ Theme Tracker Biotechnology & Healthcare Ⓛ Pharmaceuticals Markets

Potential Pfizer-Seagen Tie Up Could Mark Largest Deal in Years, Continue to Propel Biopharma M&A Trend

A potential acquisition of Seagen by Pfizer, likely in the neighborhood of $40.0 billion, would be the biggest biopharma deal…

McAlinden Research PartnersFebruary 27, 2023

★ Daily Intelligence Briefings (DIBs)⦁ Theme Tracker Biotechnology & Healthcare Ⓛ Pharmaceuticals Technology

AI Applications on the Rise in Healthcare, Boosting Biopharma and Diagnostics Efficiency

Expectations for AI in healthcare, particularly biopharma and diagnostics, have been high for several years now. New partnerships and acquisitions may…

McAlinden Research PartnersJanuary 17, 2023

★ Daily Intelligence Briefings (DIBs)⦁ Theme Tracker Biotechnology & Healthcare Ⓛ Pharmaceuticals Markets

Price Hikes and Dealmaking Potential Are Key Pharma Catalysts for 2023

The biopharma industry is kicking off the year with price hikes and some early signs of a sustained uptick in…

McAlinden Research PartnersJanuary 5, 2023

★ Daily Intelligence Briefings (DIBs)⦁ Theme Tracker Biotechnology & Healthcare Ⓛ Pharmaceuticals Markets

Another Blockbuster Biopharma Acquisition on Deck, May Set the Stage for Breakout M&A Activity in 2023

Three pharma giants are in the running to purchase Horizon Therapeutics in what will likely be a larger deal than…

McAlinden Research PartnersDecember 1, 2022

★ Daily Intelligence Briefings (DIBs)⦁ Theme Tracker Biotechnology & Healthcare Ⓛ Gene Editing Ⓛ Pharmaceuticals Markets

Pharma Fires Up More M&A Deals in Genetic Medicine as First CRISPR Drug Moves Closer to Commercialization

Mergers and Acquisitions in the biopharma space continue to heat up, fueling a significant increase in large deals through the first 9…

McAlinden Research PartnersOctober 19, 2022

★ Daily Intelligence Briefings (DIBs)⦁ Theme Tracker Biotechnology & Healthcare Ⓛ Pharmaceuticals Markets

Biopharma Space Showing Signs of a Burgeoning Buying Spree

M&A activity is picking up among pharmaceutical firms with large cash balances. Pfizer and Amgen have each closed a multi-billion…

McAlinden Research PartnersAugust 9, 2022

★ Daily Intelligence Briefings (DIBs)⦁ Theme Tracker Biotechnology & Healthcare Ⓛ Pharmaceuticals Politics & Policy

COVID Vaccines Continue to Drive Significant Pharma Revenues as BA.5 Variant Cases on the Rise

Pharma giants Pfizer and Moderna just secured multi-billion dollar deals to supply the US government with more than 170 million…

McAlinden Research PartnersAugust 1, 2022

★ Daily Intelligence Briefings (DIBs)⦁ Theme Tracker Biotechnology & Healthcare Ⓛ Pharmaceuticals Markets

Major Patent Cliff Closes in on Big Pharma, Bargain-Priced Acquisitions Could Bolster Their Pipelines

Last year marked one of the least active years for biopharma merger and acquisition (M&A) activity in a decade. The first…

McAlinden Research PartnersJuly 14, 2022

★ Daily Intelligence Briefings (DIBs)Biotechnology & Healthcare Ⓛ Pharmaceuticals Markets

Big Pharma Set to Let Biotech Bleed Continue Before Deploying Massive Cash Balances

Throughout the past few months, MRP has highlighted significant cash balances among many biopharmaceutical giants. Though hundreds of billions of dollars…

McAlinden Research PartnersJune 14, 2022

Pharma

Pfizer’s M&A Strategy Sketches Roadmap for Pharma to Rebuild Pipelines, Overcome Patent Cliffs

Potential Pfizer-Seagen Tie Up Could Mark Largest Deal in Years, Continue to Propel Biopharma M&A Trend

AI Applications on the Rise in Healthcare, Boosting Biopharma and Diagnostics Efficiency

Price Hikes and Dealmaking Potential Are Key Pharma Catalysts for 2023

Another Blockbuster Biopharma Acquisition on Deck, May Set the Stage for Breakout M&A Activity in 2023

Pharma Fires Up More M&A Deals in Genetic Medicine as First CRISPR Drug Moves Closer to Commercialization

Biopharma Space Showing Signs of a Burgeoning Buying Spree

COVID Vaccines Continue to Drive Significant Pharma Revenues as BA.5 Variant Cases on the Rise

Major Patent Cliff Closes in on Big Pharma, Bargain-Priced Acquisitions Could Bolster Their Pipelines

Big Pharma Set to Let Biotech Bleed Continue Before Deploying Massive Cash Balances

Joe Mac’s Viewpoint

The Newest Market Insights

Browse by Sector

About Us

Terms & Privacy